<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03760952</url>
  </required_header>
  <id_info>
    <org_study_id>IMA-SCREENING</org_study_id>
    <nct_id>NCT03760952</nct_id>
  </id_info>
  <brief_title>Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling</brief_title>
  <official_title>Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immatics US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immatics US, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This screening study will identify HLA molecular subtype positive and tumor antigen target(s)&#xD;
      positive patients who may be eligible for enrollment into Immatics clinical studies. This&#xD;
      screening study is intended for patients with advanced and/or metastatic solid cancers. No&#xD;
      treatment intervention will occur as part of this screening study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this screening study is to identify human leukocyte antigen (HLA) molecular&#xD;
      subtype positive and tumor antigen target(s) positive patients. No treatment intervention&#xD;
      will occur as part of this screening study.&#xD;
&#xD;
      After diagnosis of advanced and/or solid metastatic cancers, patients will be tested for HLA&#xD;
      molecular subtype positivity. Patients that are HLA molecular subtype positive are then&#xD;
      assessed to determine if their tumor antigen target(s) is positive (biopsy screening). Fresh&#xD;
      tumor tissue obtained by a biopsy for this screening study will be required. If the patient&#xD;
      is undergoing a surgical procedure directed towards tumor or palliative treatment (e.g., a&#xD;
      resection, debulking surgery, etc.) and has consented to the study, then fresh tissue may be&#xD;
      collected during the procedure to avoid the patient being subjected to another biopsy.&#xD;
&#xD;
      Tumor antigen targets in fresh tumor samples will be determined by an in vitro diagnostic&#xD;
      (IVD) assay. Therefore, any remaining tumor specimens may be used for exploratory biomarker&#xD;
      analyses and validation studies for regulatory approval.&#xD;
&#xD;
      Immatics is conducting clinical studies which target patients with advanced and/or metastatic&#xD;
      solid cancers. Patients who are HLA subtype phenotype positive and whose tumors express one&#xD;
      or more of the tumor antigen targets of interest may be eligible for ongoing clinical studies&#xD;
      of adoptive cell therapy (ACT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of patients with protocol-specified HLA subtype</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of patients with expression of analyzed tumor antigen targets</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Incidence of antigen target expression in solid tumors</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of antigen target expression in fresh and FFPE tumor samples</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Refractory Cancer</condition>
  <condition>Recurrent Cancer</condition>
  <condition>Adult Solid Tumor</condition>
  <condition>Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor Biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed advanced and/or metastatic solid tumors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed an Informed Consent Form (ICF)&#xD;
&#xD;
          2. Patients ≥ 18 years of age&#xD;
&#xD;
          3. Patients with confirmed advanced and/or metastatic solid tumors.&#xD;
&#xD;
          4. For liver cancer patients, the diagnosis must be confirmed&#xD;
&#xD;
               -  Pathological diagnosis of liver cancer based on biopsy/resection is required&#xD;
&#xD;
               -  For patients without pathological diagnosis, an imaging technique obtained by&#xD;
                  computed tomography (CT) scan or magnetic resonance imaging (MRI) is needed.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 0-1&#xD;
&#xD;
          6. Life expectancy &gt; 6 months&#xD;
&#xD;
          7. There is no limitation for prior anti-cancer treatments&#xD;
&#xD;
          8. HLA molecular phenotype positive.&#xD;
&#xD;
          9. Measurable disease according to Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST)1.1&#xD;
&#xD;
         10. At least one lesion considered accessible for biopsy unless fresh tumor tissue is&#xD;
             being collected during a surgical procedure directed towards tumor treatment or&#xD;
             palliative therapy or the patient has uterine cancer (including endometrial cancer or&#xD;
             uterine carcinosarcoma) or melanoma&#xD;
&#xD;
         11. Patient has adequate pulmonary function&#xD;
&#xD;
         12. Acceptable organ and marrow function&#xD;
&#xD;
         13. Acceptable coagulation status&#xD;
&#xD;
         14. Adequate hepatic function&#xD;
&#xD;
         15. Acceptable levels of serum creatinine&#xD;
&#xD;
         16. For liver cancer patients only, Child-Pugh score of &lt; 6&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of other malignancies (except for adequately treated basal or squamous cell&#xD;
             carcinoma or carcinoma in situ) within the last 3 years&#xD;
&#xD;
          2. Patients with primary central nervous system (CNS)/brain tumors&#xD;
&#xD;
          3. Patients whose tumors have very low expression of tumor antigen targets such as kidney&#xD;
             chromophobe, thyroid carcinoma, and prostate adenocarcinoma&#xD;
&#xD;
          4. Patients who are pregnant or are breastfeeding&#xD;
&#xD;
          5. Patients with serious autoimmune disease Note: At the discretion of the investigator,&#xD;
             these patients may be included if their disease is well controlled without the use of&#xD;
             immunosuppressive agents&#xD;
&#xD;
          6. Patients with prior stem cell transplantation or solid organ transplantation&#xD;
&#xD;
          7. Any condition contraindicating leukapheresis&#xD;
&#xD;
          8. Patients with any of the following cardiac conditions: uncontrolled hypertension&#xD;
             despite optimal therapy, uncontrolled angina, ventricular arrhythmias, congestive&#xD;
             heart failure, baseline left ventricular ejection fraction ≤ 50%, prior or current&#xD;
             cardiomyopathy, atrial fibrillation with heart rate &gt; 100 bpm, unstable ischemic heart&#xD;
             disease&#xD;
&#xD;
          9. Patients with active diverticulitis, intra-abdominal abscess, or GI obstruction&#xD;
&#xD;
         10. Patients with active pneumonitis&#xD;
&#xD;
         11. Patients with active (uncontrolled/untreated) brain metastases NOTE: Patients with a&#xD;
             history of brain metastases may be eligible, if an imaging scan with contrast&#xD;
             enhancement not older than 4 weeks is able to exclude the existence of currently&#xD;
             active brain metastasis.&#xD;
&#xD;
         12. History of hypersensitivity on fludarabine (FLU), cyclophosphamide (CY), or&#xD;
             interleukin (IL)-2&#xD;
&#xD;
         13. History of current immunodeficiency disease or prior treatment compromising immune&#xD;
             function at the discretion of the investigator.&#xD;
&#xD;
         14. Patients with Grade 3 or Grade 4 immune-related toxicities related to checkpoint&#xD;
             inhibitors or patients requiring corticosteroid treatment (≥ 10 mg/day prednisone or&#xD;
             equivalent dose).&#xD;
&#xD;
         15. Patients with bleeding diathesis or coagulopathy&#xD;
&#xD;
         16. Any serious and/or unstable pre-existing medical, psychiatric disorder or other&#xD;
             conditions that could interfere with patient's safety&#xD;
&#xD;
         17. HIV infection, active hepatitis B or C infection. History of treated hepatitis B or C&#xD;
             is permitted if the viral load is undetectable per qPCR and/or nucleic acid testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cedrik Britten, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Immatics US</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge Rivas, MD</last_name>
    <phone>346-204-5350</phone>
    <email>ctgovinquiries@immatics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gary F Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Luke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Immatics US</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Rivas, MD, PhD</last_name>
      <phone>346-204-5350</phone>
      <email>ctgovinquiries@immatics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julio Peguero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 29, 2018</study_first_submitted>
  <study_first_submitted_qc>November 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-cell therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Screening</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Previously Treated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

